Skip to main content

American Heart Association Archives

Study shows liraglutide results in increased insulin sensitivity independent of weight loss

Jan. 4, 2024—  by Jill Clendening A new study published in the journal Diabetes demonstrates that a glucagon-like peptide-1 receptor (GLP-1R) agonist, a member of a class of medication used to treat Type 2 diabetes and obesity, can lead to a rapid improvement in insulin sensitivity. Insulin sensitivity is how responsive cells are to insulin, an essential...

Read more


MicroRNAs in immune cells help protect against metabolic defects in obesity: study

Sep. 5, 2023—Vanderbilt researchers have demonstrated that a cluster of microRNAs — small pieces of RNA that regulate gene expression — work in a type of immune cells called macrophages to help protect against metabolic defects in obesity.

Read more


Targeting calcium handling in A-fib

Jun. 8, 2023—The drug ent-verticilide reduced A-fib incidence and duration in an animal model, suggesting it may be a viable therapeutic option.

Read more


Genetics and chronic pain

Apr. 20, 2023—Polygenic risk scores — scores that reflect the influence of common genetic variants — could be used to predict the likelihood of developing chronic overlapping pain conditions and guide biomarker and targeted prevention efforts.

Read more


Diabetes drug may improve asthma

Feb. 21, 2023—New biomarker finding strengthens the case for using GLP-1R agonists to treat patients with Type 2 diabetes who also suffer from asthma.

Read more


Research network yields significant findings related to obesity

Feb. 16, 2023—  by Jill Clendening In 2017, Vanderbilt University Medical Center was selected to be one of four U.S. medical centers in a Strategically Focused Research Network (SFRN) on Obesity funded by a four-year, $15 million award from the American Heart Association to study obesity and train future obesity-focused investigators. Now, the findings of the research...

Read more


Low potassium injures kidney

Jan. 19, 2023—Vanderbilt researchers have discovered that low dietary potassium causes direct kidney injury, suggesting potential new targets for treating chronic kidney disease.

Read more


Novel therapeutic target identified for chronic kidney disease

Dec. 15, 2022—Vanderbilt investigators have discovered a molecular mechanism that promotes chronic kidney disease following kidney injury.

Read more


Study defines role of steroids in congenital heart disease surgery

Nov. 10, 2022—Steroids are commonly given to infants during open-heart surgery to reduce inflammation, but whether the drugs significantly improve patient outcomes has not been settled — until now.

Read more


Study identifies key player in T cell “education”

Sep. 1, 2022—New Vanderbilt research could inform therapeutic strategies for enhancing thymic function when desired — such as during aging, recovery from radiation therapy or chemotherapy, or other conditions that reduce T cell output.

Read more


A new mechanism for lupus

Aug. 30, 2022—Vanderbilt researchers describe a new mechanism for the most common form of lupus and suggest a new treatment approach to this autoimmune disease.

Read more


Preempting sudden cardiac death

Jul. 7, 2022—A technique to characterize all variants in genes associated with arrhythmia could improve the ability to identify and preemptively treat individuals at risk for sudden cardiac death.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more